ARWR vs SMMT: Which Stock Is the Better Buy?
Arrowhead Pharmaceuticals, Inc. and Summit Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARWR vs SMMT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Summit Therapeutics Inc. (SMMT) | |
|---|---|---|
| Market cap | $10.0B | $10.4B |
| Revenue (latest FY) | $829.45M | $0 |
| Net income (latest FY) | $-1.63M | $-1.08B |
| Revenue growth (5y CAGR) | 56.6% | — |
| Net margin | -0.2% | — |
| Return on equity | -0.3% | -163.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 1 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ARWR vs SMMT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARWR's full financials → Open SMMT's full financials →More comparisons
Frequently asked questions
Which is bigger, ARWR or SMMT?
Summit Therapeutics Inc. is larger by market capitalization — $10.4B versus $10.0B.
Which grows faster, ARWR or SMMT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ARWR fundamentals → · SMMT fundamentals → · All 1,500+ companies → · Free screener →